{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:26:29Z","timestamp":1789424789393,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.vhri.2023.11.004","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T22:18:52Z","timestamp":1704406732000},"page":"108-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil"],"prefix":"10.1016","volume":"40","author":[{"given":"Br\u00edgida Dias","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"D\u2019Athayde Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9rica N\u00fabia","family":"Cardoso Cirilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9fani Sousa","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara Corr\u00eaa","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia Fernandes","family":"Probst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vhri.2023.11.004_bib1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q\u2013linked spinal muscular atrophy \u2013 a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"10.1016\/j.vhri.2023.11.004_bib2","first-page":"6544","article-title":"Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia","volume":"269","author":"Wang","year":"2022","journal-title":"J\u00a0Neurol"},{"issue":"1","key":"10.1016\/j.vhri.2023.11.004_bib3","article-title":"Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients","volume":"7","author":"Malone","year":"2019","journal-title":"J\u00a0Mark Access Health Policy"},{"issue":"6","key":"10.1016\/j.vhri.2023.11.004_bib4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jval.2020.09.021","article-title":"Early cost-effectiveness of onasemnogene Abeparvovec-xioi (Zolgensma) and nusinersen (Spinraza) treatment for spinal muscular atrophy I in the Netherlands with relapse scenarios","volume":"24","author":"Broekhoff","year":"2021","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.vhri.2023.11.004_bib5","first-page":"437","article-title":"Onasemnogene Abeparvovec (AVXS-101) for the Treatment of Spinal Muscular Atrophy","volume":"26","author":"Naveed","year":"2021","journal-title":"J\u00a0Pediatr Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.vhri.2023.11.004_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12962-020-00234-8","article-title":"Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US","volume":"18","author":"Thokala","year":"2020","journal-title":"Cost Eff Resour Alloc"},{"issue":"1","key":"10.1016\/j.vhri.2023.11.004_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2023.11.004_bib16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12939-020-01315-z","article-title":"Why do some countries do better or worse in life expectancy relative to income? An analysis of Brazil, Ethiopia, and the United States of America","volume":"19","author":"Freeman","year":"2020","journal-title":"Int J Equity Health"},{"issue":"10","key":"10.1016\/j.vhri.2023.11.004_bib17","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1080\/03007995.2021.1947216","article-title":"Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1","volume":"37","author":"Bischof","year":"2021","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1016\/j.vhri.2023.11.004_bib18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/cer-2021-0216","article-title":"How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison","volume":"11","author":"Ribero","year":"2022","journal-title":"J\u00a0Comp Eff Res"},{"issue":"18","key":"10.1016\/j.vhri.2023.11.004_bib19","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.vhri.2023.11.004_bib20","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","article-title":"Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial","volume":"21","author":"Masson","year":"2022","journal-title":"Lancet Neurol"},{"issue":"18","key":"10.1016\/j.vhri.2023.11.004_bib21","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.vhri.2023.11.004_bib22","unstructured":"Castro D, Farrar MA, Finkel R, et\u00a0al. Longer-term assessment of the safety and efficacy of nusinersen for the treatment of infantile-onset spinal muscular atrophy (SMA): an interim analysis of the SHINE study. Paper presented at: American Academy of Neurology Annual Meeting; April 21,\u00a02018."},{"key":"10.1016\/j.vhri.2023.11.004_bib23","author":"Dean"},{"issue":"9","key":"10.1016\/j.vhri.2023.11.004_bib24","doi-asserted-by":"crossref","first-page":"A725","DOI":"10.1016\/j.jval.2017.08.1962","article-title":"The utility of different Approachs to developing health utilities data in childhood rare diseases \u2013 a case study in spinal muscular atrophy (SMA)","volume":"20","author":"Thompson","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.11.004_bib25","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2147\/CEOR.S214084","article-title":"Estimation of the quality of life benefits associated with treatment for spinal muscular atrophy<\/p&gt","volume":"11","author":"Lloyd","year":"2019","journal-title":"ClinicoEconomics Outcomes Res"},{"issue":"1","key":"10.1016\/j.vhri.2023.11.004_bib26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12955-021-01671-6","article-title":"EQ-5D Brazilian population norms","volume":"19","author":"Santos","year":"2021","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.vhri.2023.11.004_bib28","unstructured":"Brazil. National Health Surveillance Agency. Medicines Market Regulation Chamber. Proc(25351):855127\/2020-68. Company Novartis Bioci\u00eancias S.A. Product Zolgensma\u00ae. aqui falta colocar o site, eu n\u00e3o encontrei."},{"issue":"3","key":"10.1016\/j.vhri.2023.11.004_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2022-008637","article-title":"Ultraexpensive gene therapies, industry interests and the right to health: the case of onasemnogene abeparvovec in Brazil","volume":"7","author":"Ivama-Brummell","year":"2022","journal-title":"BMJ Glob Health"},{"issue":"1","key":"10.1016\/j.vhri.2023.11.004_bib34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s13023-021-02015-9","article-title":"Growth patterns in children with spinal muscular atrophy","volume":"16","author":"de Amicis","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.vhri.2023.11.004_bib35","first-page":"145","article-title":"Spinal muscular atrophy (SMA-5q) care-associated costs in Brazil","volume":"13","author":"Etges","year":"2021","journal-title":"J Bras Econ Sa\u00fade"},{"issue":"1","key":"10.1016\/j.vhri.2023.11.004_bib37","first-page":"101","article-title":"Risk Sharing Agreement: a pilot project in the Brazilian Unified Health System","volume":"14","author":"Vianna","year":"2022","journal-title":"J\u00a0Bras Econ Sa\u00fade"},{"key":"10.1016\/j.vhri.2023.11.004_bib38","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3332\/ecancer.2018.823","article-title":"Risk-sharing agreements, present and future","volume":"12","author":"Gon\u00e7alves","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.vhri.2023.11.004_bib39","article-title":"Influencing factors of health technology assessment to orphan drugs: empirical evidence in England, Scotland, Canada, and Australia","volume":"10","author":"Zhou","year":"2022","journal-title":"Front Public Health"},{"issue":"5","key":"10.1016\/j.vhri.2023.11.004_bib40","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jval.2018.03.004","article-title":"Challenges in research and health technology assessment of rare disease technologies: report of the ISPOR rare disease Special Interest Group","volume":"21","author":"Nestler-Parr","year":"2018","journal-title":"Value Health"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109923001255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109923001255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:14:54Z","timestamp":1761941694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109923001255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":26,"alternative-id":["S2212109923001255"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2023.11.004","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2023.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}